Taaleri Real Estate and Keva (Finland’s largest pension insurer, responsible for providing pensions ...
Cost-effective coatings for hydrogen and metallisation applications Seizing opportunities in Chinese...
We forecast Q4 revenue of NOK 243m, +15% y-o-y Doro acquisition closed, could lift '28e EBITA by ~12...
Q4'24e organic sales growth of 24% y-o-y Minor estimate changes FVR of SEK 30-45 reiterated What to...
Redeye comments on the outcome of Ngenic’s rights issue, which was subscribed to 88%, injecting Ngen...
According to preliminary information, annual EBITDA will be EUR 4-6m in 2024 (old guidance EUR 4-8m,...
In Q4-24, Eevia Health Plc (publ) (“Eevia” or “the Company”) launched a transformational restructuri...
SEK 120+7m retrofit order to be delivered in 2025-2035 Covers our '25e-'28e Retrofit assumptions, ~1...
Q4e: 15% organic sales growth y-o-y, 11% adj. EBITA margin Expect a solid Q4, partly on light comps ...
Redeye comments on Heliospectra’s proposed rights issue, fully secured by its main owner, Weland Stå...
Redeye offers a preview of Polygien's Q4 results set to be released on February 13.
The greatest excitement regarding Aspo's Q4 results faded when the company downgraded its full-year ...
Ahead of Atria’s Q4 report, we maintain our estimates intact.
Preliminary Q4 sales SEK 8.2m, cash balance SEK 17m '25e-'26e sales and EBIT unchanged, EPS changes ...
Q4 due on 13 February Negative organic growth but +14% adj.
